REGRESS Trial: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
Rim Halaby (talk | contribs)
CMEUser, Bureaucrats, nocaptcha, Administrators
27,346 edits
Created page with "__NOTOC__ {{High density lipoprotein}} {{CMG}} ==REGRESS Trial== ===Objective=== To evaluate the effects of cholesterol lowering therapy, using a hydroxymethyl glutaryl c..."
 
Rim Halaby (talk | contribs)
CMEUser, Bureaucrats, nocaptcha, Administrators
27,346 edits
No edit summary
 
Line 3: Line 3:


{{CMG}}
{{CMG}}
==REGRESS Trial==
==Objective==
===Objective===
To evaluate the effects of [[cholesterol]] lowering therapy, using a hydroxymethyl glutaryl coenzyme A reductase inhibitor ([[pravastatin]]) in symptomatic men with [[coronary artery disease]] ([[CAD]]).
To evaluate the effects of [[cholesterol]] lowering therapy, using a hydroxymethyl glutaryl coenzyme A reductase inhibitor ([[pravastatin]]) in symptomatic men with [[coronary artery disease]] ([[CAD]]).


===Methods===
==Methods==
Regression Growth Evaluation Statin Study (REGRESS) was a multicentered, prospective, double-blinded, randomized, placebo-controlled trial that enrolled 885 men with established coronary artery disease with total cholesterol levels in the range of 155 and 310 mg/dL. The patients were randomized into two groups, treatment and control and followed up for two years. Effect of pravastatin on progression and regression of coronary atherosclerosis was assessed by quantitative [[coronary arteriography]]. All the patients received routine antianginal treatment for the duration of the trial.  
Regression Growth Evaluation Statin Study (REGRESS) was a multicentered, prospective, double-blinded, randomized, placebo-controlled trial that enrolled 885 men with established coronary artery disease with total cholesterol levels in the range of 155 and 310 mg/dL. The patients were randomized into two groups, treatment and control and followed up for two years. Effect of pravastatin on progression and regression of coronary atherosclerosis was assessed by quantitative [[coronary arteriography]]. All the patients received routine antianginal treatment for the duration of the trial.  


===Results===
==Results==
Percent diameter stenosis before angioplasty was 78 +/- 14% (mean +/- SD) in the pravastatin group and 80 +/- 14% in the placebo group (p = 0.46). At follow-up, the percent diameter [[stenosis]] was 32 +/- 23% in the pravastatin group and 45 +/- 29% in the [[placebo]] group (p < 0.001). Clinical restenosis was significantly lower in the pravastatin group (7%) compared with the placebo group (29%) (p < 0.001).
Percent diameter stenosis before angioplasty was 78 +/- 14% (mean +/- SD) in the pravastatin group and 80 +/- 14% in the placebo group (p = 0.46). At follow-up, the percent diameter [[stenosis]] was 32 +/- 23% in the pravastatin group and 45 +/- 29% in the [[placebo]] group (p < 0.001). Clinical restenosis was significantly lower in the pravastatin group (7%) compared with the placebo group (29%) (p < 0.001).


===Conclusion===
==Conclusion==
In symptomatic men with significant coronary artery disease and normal to moderately elevated serum cholesterol, less progression of coronary atherosclerosis and fewer new cardiovascular events were observed in the group of patients treated with pravastatin than in the placebo group.<ref name="pmid7743614">{{cite journal |author=Jukema JW, Bruschke AV, van Boven AJ, ''et al.'' |title=Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS) |journal=Circulation |volume=91 |issue=10 |pages=2528–40 |year=1995 |month=May |pmid=7743614 |doi= |url=}}</ref><ref name="pmid8840836">{{cite journal |author=van Boven AJ, Jukema JW, Zwinderman AH, Crijns HJ, Lie KI, Bruschke AV |title=Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. REGRESS Study Group |journal=Circulation |volume=94 |issue=7 |pages=1503–5 |year=1996 |month=October |pmid=8840836 |doi= |url=}}</ref><ref name="pmid11018193">{{cite journal |author=Mulder HJ, Bal ET, Jukema JW, ''et al.'' |title=Pravastatin reduces restenosis two years after percutaneous transluminal coronary angioplasty (REGRESS trial) |journal=Am. J. Cardiol. |volume=86 |issue=7 |pages=742–6 |year=2000 |month=October |pmid=11018193 |doi= |url=}}</ref><ref name="pmid1486543">{{cite journal |author=Barth JD, Zonjee MM |title=Regression growth evaluation statin study (REGRESS): study design and baseline characteristics in 600 patients. The REGRESS Research Group |journal=Can J Cardiol |volume=8 |issue=9 |pages=925–32 |year=1992 |month=November |pmid=1486543 |doi= |url=}}</ref>
In symptomatic men with significant coronary artery disease and normal to moderately elevated serum cholesterol, less progression of coronary atherosclerosis and fewer new cardiovascular events were observed in the group of patients treated with pravastatin than in the placebo group.<ref name="pmid7743614">{{cite journal |author=Jukema JW, Bruschke AV, van Boven AJ, ''et al.'' |title=Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS) |journal=Circulation |volume=91 |issue=10 |pages=2528–40 |year=1995 |month=May |pmid=7743614 |doi= |url=}}</ref><ref name="pmid8840836">{{cite journal |author=van Boven AJ, Jukema JW, Zwinderman AH, Crijns HJ, Lie KI, Bruschke AV |title=Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. REGRESS Study Group |journal=Circulation |volume=94 |issue=7 |pages=1503–5 |year=1996 |month=October |pmid=8840836 |doi= |url=}}</ref><ref name="pmid11018193">{{cite journal |author=Mulder HJ, Bal ET, Jukema JW, ''et al.'' |title=Pravastatin reduces restenosis two years after percutaneous transluminal coronary angioplasty (REGRESS trial) |journal=Am. J. Cardiol. |volume=86 |issue=7 |pages=742–6 |year=2000 |month=October |pmid=11018193 |doi= |url=}}</ref><ref name="pmid1486543">{{cite journal |author=Barth JD, Zonjee MM |title=Regression growth evaluation statin study (REGRESS): study design and baseline characteristics in 600 patients. The REGRESS Research Group |journal=Can J Cardiol |volume=8 |issue=9 |pages=925–32 |year=1992 |month=November |pmid=1486543 |doi= |url=}}</ref>


Line 22: Line 21:
[[Category:Lipopedia]]
[[Category:Lipopedia]]
[[Category:HDL]]
[[Category:HDL]]
[[Category:Clinical trials]]

Latest revision as of 23:20, 17 September 2013

High Density Lipoprotein Microchapters

Home

Patient information

Overview

Historical Perspective

Classification

Physiology

Pathophysiology

Causes

Low HDL
High HDL

Epidemiology and Demographics

Screening

Natural History, Complications and Prognosis

Diagnosis

HDL Laboratory Test

Treatment

Medical Therapy

Prevention

Future or Investigational Therapies

Clinical Trials

Landmark Trials

List of All Trials

Case Studies

Case #1

REGRESS Trial On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of REGRESS Trial

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on REGRESS Trial

CDC on REGRESS Trial

REGRESS Trial in the news

Blogs on REGRESS Trial

Directions to Hospitals Treating High density lipoprotein

Risk calculators and risk factors for REGRESS Trial

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Objective

To evaluate the effects of cholesterol lowering therapy, using a hydroxymethyl glutaryl coenzyme A reductase inhibitor (pravastatin) in symptomatic men with coronary artery disease (CAD).

Methods

Regression Growth Evaluation Statin Study (REGRESS) was a multicentered, prospective, double-blinded, randomized, placebo-controlled trial that enrolled 885 men with established coronary artery disease with total cholesterol levels in the range of 155 and 310 mg/dL. The patients were randomized into two groups, treatment and control and followed up for two years. Effect of pravastatin on progression and regression of coronary atherosclerosis was assessed by quantitative coronary arteriography. All the patients received routine antianginal treatment for the duration of the trial.

Results

Percent diameter stenosis before angioplasty was 78 +/- 14% (mean +/- SD) in the pravastatin group and 80 +/- 14% in the placebo group (p = 0.46). At follow-up, the percent diameter stenosis was 32 +/- 23% in the pravastatin group and 45 +/- 29% in the placebo group (p < 0.001). Clinical restenosis was significantly lower in the pravastatin group (7%) compared with the placebo group (29%) (p < 0.001).

Conclusion

In symptomatic men with significant coronary artery disease and normal to moderately elevated serum cholesterol, less progression of coronary atherosclerosis and fewer new cardiovascular events were observed in the group of patients treated with pravastatin than in the placebo group.[1][2][3][4]

References

  1. ↑ Jukema JW, Bruschke AV, van Boven AJ; et al. (1995). "Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)". Circulation. 91 (10): 2528–40. PMID 7743614. Unknown parameter |month= ignored (help)
  2. ↑ van Boven AJ, Jukema JW, Zwinderman AH, Crijns HJ, Lie KI, Bruschke AV (1996). "Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. REGRESS Study Group". Circulation. 94 (7): 1503–5. PMID 8840836. Unknown parameter |month= ignored (help)
  3. ↑ Mulder HJ, Bal ET, Jukema JW; et al. (2000). "Pravastatin reduces restenosis two years after percutaneous transluminal coronary angioplasty (REGRESS trial)". Am. J. Cardiol. 86 (7): 742–6. PMID 11018193. Unknown parameter |month= ignored (help)
  4. ↑ Barth JD, Zonjee MM (1992). "Regression growth evaluation statin study (REGRESS): study design and baseline characteristics in 600 patients. The REGRESS Research Group". Can J Cardiol. 8 (9): 925–32. PMID 1486543. Unknown parameter |month= ignored (help)
Retrieved from "https://www.wikidoc.org/index.php?title=REGRESS_Trial&oldid=905937"